Diagnosis and treatment of Hymenoptera venom allergy in adults : A single-center experience in Lithuania
© 2024 The Authors..
Background: Venom-specific immunotherapy (VIT) is a major treatment for patients allergic to Hymenoptera venom. Thus, correct diagnosis of sensitization, identification of the risk factors, and choice of venom for the treatment are the key issues.
Objective: We aimed to describe diagnostic and treatment experience data of VIT performed in a single center in Lithuania.
Methods: In this retrospective study, we analyzed 9 years of clinical data (severity of the allergic reaction, recognition of the culprit insects, diagnostics, VIT protocol safety and efficacy, sting challenge outcomes) of patients treated with cluster VIT. Sting challenge helped to reveal the influence of venom preparation quality and to adjust the dosage of venom.
Results: Data from 83 patients were analyzed. Double sensitization confirmed by component diagnosis was found in 39.4% (13/33), and double immunotherapy was initiated in 9.1% (n = 3/33). The cluster immunotherapy protocol was used in 81 patients. Systemic reactions occurred in 7.4% (n = 6/81) patients during the build-up phase. VIT failure was related to bee venom immunotherapy and systemic reactions during a build-up phase. The efficacy in the short term of our approach to cluster VIT was confirmed by the sting challenge in 97% (42/43). Nine patients (10.8%, n = 9/83) voluntarily stopped the treatment due to a lack of motivation.
Conclusion: Our protocol regarding the investigation and treatment of patients allergic to Hymenoptera venom has been safe and effective. Patient's motivation to continue VIT is one of the concerns, but the biggest challenge is the patients with bee venom allergy and repeated systemic reactions during VIT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
The World Allergy Organization journal - 17(2024), 3 vom: 30. März, Seite 100884 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cerniauskas, Kestutis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cluster immunotherapy |
|---|
| Anmerkungen: |
Date Revised 16.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.waojou.2024.100884 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369764021 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369764021 | ||
| 003 | DE-627 | ||
| 005 | 20240316233104.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.waojou.2024.100884 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM369764021 | ||
| 035 | |a (NLM)38486719 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cerniauskas, Kestutis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and treatment of Hymenoptera venom allergy in adults |b A single-center experience in Lithuania |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Background: Venom-specific immunotherapy (VIT) is a major treatment for patients allergic to Hymenoptera venom. Thus, correct diagnosis of sensitization, identification of the risk factors, and choice of venom for the treatment are the key issues | ||
| 520 | |a Objective: We aimed to describe diagnostic and treatment experience data of VIT performed in a single center in Lithuania | ||
| 520 | |a Methods: In this retrospective study, we analyzed 9 years of clinical data (severity of the allergic reaction, recognition of the culprit insects, diagnostics, VIT protocol safety and efficacy, sting challenge outcomes) of patients treated with cluster VIT. Sting challenge helped to reveal the influence of venom preparation quality and to adjust the dosage of venom | ||
| 520 | |a Results: Data from 83 patients were analyzed. Double sensitization confirmed by component diagnosis was found in 39.4% (13/33), and double immunotherapy was initiated in 9.1% (n = 3/33). The cluster immunotherapy protocol was used in 81 patients. Systemic reactions occurred in 7.4% (n = 6/81) patients during the build-up phase. VIT failure was related to bee venom immunotherapy and systemic reactions during a build-up phase. The efficacy in the short term of our approach to cluster VIT was confirmed by the sting challenge in 97% (42/43). Nine patients (10.8%, n = 9/83) voluntarily stopped the treatment due to a lack of motivation | ||
| 520 | |a Conclusion: Our protocol regarding the investigation and treatment of patients allergic to Hymenoptera venom has been safe and effective. Patient's motivation to continue VIT is one of the concerns, but the biggest challenge is the patients with bee venom allergy and repeated systemic reactions during VIT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cluster immunotherapy | |
| 650 | 4 | |a Lithuania | |
| 650 | 4 | |a Retrospective study | |
| 650 | 4 | |a Venom hypersensitivity | |
| 700 | 1 | |a Rudyte, Justina |e verfasserin |4 aut | |
| 700 | 1 | |a Linauskiene, Kotryna |e verfasserin |4 aut | |
| 700 | 1 | |a Chomiciene, Anzelika |e verfasserin |4 aut | |
| 700 | 1 | |a Griguola, Linas |e verfasserin |4 aut | |
| 700 | 1 | |a Malinauskiene, Laura |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The World Allergy Organization journal |d 2008 |g 17(2024), 3 vom: 30. März, Seite 100884 |w (DE-627)NLM19437937X |x 1939-4551 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g number:3 |g day:30 |g month:03 |g pages:100884 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.waojou.2024.100884 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |e 3 |b 30 |c 03 |h 100884 | ||